NTRK1 and inflammatory myofibroblastic tumor: Oncogenic fusions in NTRK family receptor tyrosine kinases had been identified in several cancers and could serve as therapeutic targets, for instance in spitz tumors (30), fibrosarcoma (31), gastrointestinal stromal tumors (32), and inflammatory myofibroblastic tumors (33).